Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lintuzumab, a humanized monoclonal antibody that targets CD33 antigen in hematologic malignancies
Subscribe to our email newsletter
Seattle Genetics has reported multiple objective responses at well-tolerated doses from a phase-I clinical trial of lintuzumab (SGN-33) in patients with acute myeloid leukemia (AML).
Lintuzumab is a humanized monoclonal antibody that targets CD33 antigen, which is expressed on a number of hematologic malignancies, including AML and myelodysplastic syndromes (MDS).
The company is also evaluating lintuzumab for MDS, including a phase-I trial in combination with Revlimid (lenalidomide) and a planned phase II clinical trial combined with Vidaza (azacitidine).
Clay Siegall, President and CEO of Seattle, said: “We are pleased by the findings from this large single-agent phase I trial demonstrating that lintuzumab was well-tolerated and induced objective responses in patients with AML.”
“We continue to believe that the path forward with lintuzumab will be as a combination agent, and our clinical development program is focused primarily on a phase IIb trial combining lintuzumab with low-dose chemotherapy to determine if lintuzumab can extend overall survival in older AML patients,” he added.